New Hampshire Secures $29.5 Million from Purdue Pharma Settlement to Combat Opioid Crisis

New Hampshire is set to receive more than $29.5 million over the next decade as part of the nationwide $7.4 billion settlement with Purdue Pharma and the Sackler family, marking the end of a ten-year legal battle that held the pharmaceutical giant accountable for its role in fueling the opioid epidemic.

The settlement, which became legally effective earlier this month, represents one of the largest civil resolutions in American history. State officials expect approximately $16.2 million—more than half of New Hampshire's total allocation—to be disbursed over the first three years, providing immediate resources for communities devastated by addiction.

"For too long, they profited while communities like ours paid the price," said Attorney General John Formella in a statement announcing the funds. "While no amount of money can undo the harm caused to families across New Hampshire, this agreement delivers both accountability and meaningful resources."

How the Funds Will Be Distributed

Under state law, 15% of the settlement—approximately $4.5 million—will flow directly to cities and counties based on population. The remaining 85% enters the state's Opioid Abatement Trust Fund, where an advisory commission determines which organizations and programs receive support.

This structure ensures that local municipalities have immediate access to resources while maintaining oversight for larger prevention and treatment initiatives. The commission includes representatives from public health, law enforcement, healthcare, and recovery communities.

The Human Cost in New Hampshire

The Granite State experienced the opioid crisis with particular severity. Deaths peaked in 2017 at 416 opioid-related fatalities—roughly 33.4 per 100,000 residents—among the highest rates nationally. Though numbers declined from that peak, the pandemic brought a resurgence, and 2024 saw 248 overdose deaths involving opioids.

Governor Kelly Ayotte emphasized the settlement's significance for families who lost loved ones. "The opioid crisis has devastated families in our state, and I thank the Attorney General's Office in New Hampshire and AGs across the country who have worked tirelessly to hold Purdue Pharma accountable for their role in poisoning our communities."

A Permanent Ban on the Sacklers

Beyond the financial settlement, the agreement permanently bars the Sackler family from selling opioids in the United States. This provision prevents the family, whose fortune was built largely through Purdue's aggressive marketing of OxyContin, from ever again profiting from prescription painkillers in this country.

For people struggling with opioid addiction, the settlement funds represent more than compensation—they offer a pathway to treatment and recovery in a state where access to care has often fallen short of demand.

Looking Forward

The settlement arrives as New Hampshire continues grappling with a changing drug landscape. While prescription opioid deaths have declined, fentanyl and other synthetic opioids now drive the majority of fatalities. State health officials say the funds will support evidence-based approaches including medication-assisted treatment, harm reduction services, and recovery housing.

The first tranche of funding is expected to reach programs by late summer, with the advisory commission already accepting proposals from community organizations. For a state that has lost thousands to the crisis, the settlement offers both a measure of justice and a concrete investment in preventing future tragedies.